Turnstone Biologics isn’t the only cell therapy biotech focused on tumor-infiltrating lymphocytes. With $80 million in IPO cash, it can continue clinical trials that could show whether its approach to TILs has advantages.
The company is developing tumor-infiltrating lymphocyte therapies that target patient-specific neoantigens. It plans to use the money to fund Phase I/IIa studies in solid tumors.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.